-
Money9 Covid25 Index continues to outperform Nifty50, Nifty Pharma
Money9 Covid25 Index advanced 2.78% while Nifty50 and Nifty Pharma logged gains of 0.82% and 2.57%, respectively
-
Money9 Covid25 Index & Nifty 50 hovering near their record highs
The base period for the Money9 Covid25 Index is March 24, 2020, when India went into lockdown, and the base value of the index has been kept at 100
-
Nifty50 not the only index at all-time high
This week, both Nifty and Money9 Covid25 touched their record highs of 15,469 and 312.67, respectively
-
Covid-19: Roche’s antibody cocktail priced at Rs 59,750 per dose launched in India
Cipla will distribute the product by leveraging its strong distribution strengths across India.
-
Here’s how the Money9 Covid25 index performed this week
This week, Money9 Covid25 Index outperformed the Nifty Pharma index by 1.9 percentage points but underperformed the Nifty 50 by 68 basis points
-
Money9 Covid25 Index: Check out its performance
In the current week, benchmark index Nifty 50 ended with losses of 1% whereas Money9 Covid25 Index fell 0.7%
-
Launching Money9 Covid25 Index: These 25 Covid-stocks are beating Dalal Street
The index consists of 25 Covid-stocks broadly categorised into five verticals of the healthcare industry — vaccine manufacturers, pharma companies,
